Leading topics of the 2020 J.P. Morgan Healthcare Conference included a general lack of big deals, defining digital health, and biopharma’s diversity problem.


Bayer and biotechnology company Dewpoint Therapeutics announced an option, research and license agreement worth up to $100 million.

British Columbia-based Chinook Therapeutics burst onto the scene with $65 million in hand and a goal of driving a portfolio of compounds aimed at kidney diseases into the clinic by 2021.

With $28.5 million in financing, Cambridge, Mass.-based Comet Therapeutics is emerging from stealth mode with a focus on developing a portfolio of drug candidates that centers around efforts to re-engineer CoEnzyme-A (CoA).

Thrive Earlier Detection Corp., a liquid biopsy company, raised $110 million in Series A funding.

ElevateBio, a new company focused on the development of startup cell and gene therapy companies, launched with a $150 million Series A financing round.

Nocion Therapeutics launched in Cambridge, Mass., with a $27 million series A raise this week.

Privately held Talaris Therapeutics secured $100 million in a Series A financing round as the company undergoes a rebranding with a new leadership team.

Philadelphia-based Passage Bio launched with a Series A financing round valued at $115.5 million, led by OrbiMed Advisors.